TY  -  
T1  - Janus kinases to jakinibs : from basic insights to clinical practice 
SN  -  /  
UR  - http://hdl.handle.net/10138/327839 
T3  -  
A1  - Gadina, Massimo; Le, Mimi T.; Schwartz, Daniella M.; Silvennoinen, Olli; Nakayamada, Shingo; Yamaoka, Kunihiro; O'Shea, John J. 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Cytokines are critical mediators of diverse immune and inflammatory diseases. Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance. We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - cytokines; signal transduction; Janus kinases; kinase inhibitors; autoimmunity; inflammation; MODIFYING ANTIRHEUMATIC DRUG; COMBINED IMMUNE-DEFICIENCY; SELECTIVE JAK-1 INHIBITOR; RHEUMATOID-ARTHRITIS; INADEQUATE RESPONSE; TYROSINE KINASE; PRIMARY MYELOFIBROSIS; TRANSCRIPTION FACTORS; VX-509 DECERNOTINIB; DISEASE-ACTIVITY; 1182 Biochemistry, cell and molecular biology; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -